BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-91@catalystbrief.girapphe.com
DTSTAMP:20261117T061557Z
LAST-MODIFIED:20261117T061557Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Aragon Pharmaceuticals\, Inc. — Apalutamide [Mar 2027]
DESCRIPTION:Phase 3 primary completion: An Efficacy and Safety Study of JNJ
 -56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Pr
 imary Radiation Therapy: ATLAS.\nSource: https://clinicaltrials.gov/study/
 NCT02531516\nhttps://catalystbrief.girapphe.com/e/91?lang=en\nNot investme
 nt advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/91?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
